Drug Information

Drug (ID: DG01705) and It's Reported Resistant Information

Name	Bevacizumab/Sorafenib
Synonyms	Bevacizumab/Sorafenib Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Melanoma [ICD-11: 2C30]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Mast/stem cell growth factor receptor Kit (KIT)			[1]
Molecule Alteration	Missense mutation	p.L576P (c.1727T>C)	Molecule Info
Sensitive Disease	Melanoma [ICD-11: 2C30.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data
Experiment for Molecule Alteration	ICH assay
Experiment for Drug Resistance	Radiologic assessment assay

References

Ref 1	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsInvest New Drugs. 2015 Feb;33(1):215-24. doi: 10.1007/s10637-014-0176-4. Epub 2014 Nov 4.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.